YD Bio Limited Ordinary Shares
YDES | NASDAQ
$2.63
-$0.56 (-17.55%)
At close: Sep 21, 2026, 4:00 PM ET
$2.74
+$0.11 (+4.18%)
Pre-market:
Sep 22, 2026, 4:24 AM ET
Company Profile
Breeze Holdings Acquisition Corp. is a clinical-stage biopharmaceutical company based in Taipei, Taiwan. The firm concentrates its efforts on developing medical diagnostics for cancer prevention and creating exosome-based therapeutics, both of which aim to revolutionize treatment options for diseases with significant unmet medical needs.
Key Executives
| Name | Position |
|---|---|
| Ethan Shen | CEO & Chairman |
| Edmund Hen | Chief Financial Officer |
| Benjamin Zhang | Chief Medical Officer & Director |
YD Bio Limited Ordinary Shares
| Country | Taiwan |
| IPO Date | Aug 28, 2025 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Ethan Shen |
Contact Details
No. 3, Xingnan St. Taipei,
TP 115001 Taiwan
Stock Details
| Ticker Symbol | YDES |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0002011674 |
| CUSIP Number | G98301107 |
| ISIN Number | KYG983011076 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove YDES